Quince Therapeutics, Inc. provided a business update and reported its financial results for the second quarter ended June 30, 2025. The company's existing cash position is approximately $35 million, which is expected to provide an operating runway through Phase 3 topline results and into at least the second quarter of 2026.
The company marked a major milestone with the completion of enrollment in its pivotal Phase 3 NEAT clinical trial, evaluating eDSP for the treatment of Ataxia-Telangiectasia (A-T). This achievement keeps Quince on track to deliver topline results in the first quarter of 2026.
Additionally, Quince solidified its commercial development planning by entering into a strategic relationship with Option Care Health to support the commercial launch of eDSP in the U.S. The company remains confident in its ability to achieve an NDA submission in the second half of 2026, assuming positive study results.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.